C.Q. Pharmaceutical Holding Co., Ltd. (SHE:000950)
China · Delayed Price · Currency is CNY 5.48
-0.29 (-5.03%)
Aug 21, 2026, 3:04 PM CST
SHE:000950 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 9,386 | 10,058 | 9,298 | 8,589 | 8,856 | 8,891 | |
Market Cap Growth | 0.02% | 8.18% | 8.25% | -3.02% | -0.39% | -1.06% |
Enterprise Value | 34,685 | 32,580 | 31,061 | 29,929 | 29,710 | 25,365 |
Last Close Price | 5.48 | 5.76 | 5.29 | 4.82 | 4.88 | 4.83 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 22.03 | 26.01 | 32.85 | 13.75 | 9.30 | 8.84 |
Forward PE | - | 11.88 | 13.12 | 7.26 | - | - |
PS Ratio | 0.11 | 0.12 | 0.12 | 0.11 | 0.13 | 0.14 |
PB Ratio | 0.56 | 0.61 | 0.56 | 0.56 | 0.70 | 0.76 |
P/TBV Ratio | 0.94 | 1.03 | 0.97 | 0.91 | 1.00 | 1.10 |
P/FCF Ratio | - | 22.10 | - | 32.52 | 498.57 | - |
P/OCF Ratio | - | 13.33 | - | 16.89 | 30.99 | 35.54 |
PEG Ratio | - | 0.58 | 0.58 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.42 | 0.40 | 0.39 | 0.38 | 0.44 | 0.41 |
EV/EBITDA Ratio | 22.43 | 23.39 | 20.76 | 13.58 | 12.34 | 10.81 |
EV/EBIT Ratio | 31.94 | 28.77 | 25.20 | 15.30 | 13.65 | 11.65 |
EV/FCF Ratio | - | 71.58 | - | 113.31 | 1672.55 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.50 | 1.43 | 1.48 | 1.50 | 1.92 | 1.70 |
Debt / EBITDA Ratio | 16.27 | 14.87 | 14.37 | 9.85 | 9.45 | 8.05 |
Debt / FCF Ratio | - | 52.06 | - | 87.76 | 1372.72 | - |
Net Debt / Equity Ratio | 1.21 | 1.03 | 0.91 | 0.91 | 1.33 | 1.22 |
Net Debt / EBITDA Ratio | 15.06 | 12.21 | 10.04 | 6.37 | 7.04 | 6.13 |
Net Debt / FCF Ratio | -28.29 | 37.37 | -34.33 | 53.12 | 954.49 | -60.06 |
Asset Turnover | 1.20 | 1.24 | 1.24 | 1.30 | 1.27 | 1.36 |
Inventory Turnover | 7.73 | 7.65 | 8.03 | 8.77 | 8.92 | 9.71 |
Quick Ratio | 0.95 | 0.97 | 1.04 | 1.03 | 0.95 | 1.07 |
Current Ratio | 1.20 | 1.22 | 1.30 | 1.27 | 1.20 | 1.30 |
Return on Equity (ROE) | 3.28% | 3.16% | 2.52% | 5.18% | 9.50% | 11.60% |
Return on Assets (ROA) | 0.99% | 1.06% | 1.18% | 2.03% | 2.55% | 2.95% |
Return on Invested Capital (ROIC) | 2.39% | 2.70% | 2.91% | 5.00% | 6.16% | 7.62% |
Return on Capital Employed (ROCE) | 5.70% | 5.80% | 5.50% | 9.50% | 13.20% | 12.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.60% | 3.84% | 3.04% | 7.27% | 10.75% | 11.31% |
FCF Yield | -7.63% | 4.52% | -4.70% | 3.08% | 0.20% | -2.69% |
Dividend Yield | 1.03% | 1.04% | 1.13% | 1.04% | 1.23% | 2.17% |
Payout Ratio | 24.12% | 225.89% | 395.80% | 207.96% | 97.54% | 122.08% |
Buyback Yield / Dilution | 2.78% | 0.62% | -1.94% | -0.21% | 0.12% | -0.31% |
Total Shareholder Return | 3.81% | 1.66% | -0.80% | 0.83% | 1.35% | 1.86% |